Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
3.21% $4.82
America/New_York / 22 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 230.58 mill |
EPS: | -6.47 |
P/E: | -0.740 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 47.84 mill |
Avg Daily Volume: | 0.992 mill |
RATING 2024-04-22 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Strong Buy | |
P/E: | Neutral | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.740 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.13x |
Company: PE -0.740 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.977 (-120.27%) $-5.80 |
Date: 2024-04-23 |
Expected Trading Range (DAY) |
---|
$ 4.53 - 5.11 ( +/- 6.08%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-01 | Kapusta Matthew C | Buy | 150 000 | Ordinary Shares |
2024-03-01 | Kapusta Matthew C | Buy | 259 500 | Stock Option (Right to Buy) |
2024-03-01 | Klemt Christian | Buy | 49 500 | Ordinary Shares |
2024-03-01 | Klemt Christian | Buy | 85 500 | Stock Option (Right to Buy) |
2024-03-01 | Abi-saab Walid | Buy | 49 500 | Ordinary Shares |
INSIDER POWER |
---|
73.78 |
Last 98 transactions |
Buy: 2 008 230 | Sell: 329 878 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $4.82 (3.21% ) |
Volume | 0.378 mill |
Avg. Vol. | 0.992 mill |
% of Avg. Vol | 38.11 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $5.52 | N/A | Active |
---|
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.